文献速递食管与纵隔外科

剑突下与侧肋间胸腔镜胸腺切除术治疗疑似胸腺瘤:随机对照试验结果

Subxiphoid versus lateral intercostal thoracoscopic thymectomy for suspected thymoma: Results of a randomized controlled trial.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-10-27

这项多中心、开放标签、随机优效性试验纳入101例临床诊断为Masaoka-Koga I-II期胸腺瘤的参与者,比较剑突下与侧肋间胸腔镜胸腺切除术。剑突下组术后0-7天疼痛视觉模拟量表评分曲线下面积较低(差值-4.82;98.3%CI,-8.84至-0.80),但住院时间与累积阿片类药物消耗无显著差异,两组并发症率无显著差异(7.84% vs 8.00%,P=1.000)。

要点

  • 剑突下组术后0-7天疼痛视觉模拟量表评分曲线下面积低于侧肋间组(差值-4.82;98.3%CI,-8.84至-0.80)。
  • 两组住院时间无显著差异(差值0.318;98.3%CI,-0.190至0.825)。
  • 两组术后累积阿片类药物消耗无显著差异(差值-4.630;98.3%CI,-9.530至0.272)。

核心结论

  • 在疑似Masaoka-Koga I-II期胸腺瘤患者中,与侧肋间入路相比,剑突下入路胸腔镜胸腺切除术疼痛改善,住院时间相似。

研究设计与样本

  • 多中心、开放标签、随机临床优效性试验,纳入101例临床诊断为Masaoka-Koga I-II期胸腺瘤的合格参与者,招募时间为2021年8月15日至2022年2月15日。
  • 每例入组参与者随机接受剑突下入路胸腔镜胸腺切除术或侧肋间入路胸腔镜胸腺切除术。
  • 除主要意向性治疗分析外,还对每个共同主要结局进行了符合方案集分析。

主要发现

  • 剑突下组0-7天疼痛视觉模拟量表评分曲线下面积低于侧肋间组(差值-4.82;98.3%CI,-8.84至-0.80)。
  • 两组住院时间无显著差异(差值0.318;98.3%CI,-0.190至0.825)。
  • 两组术后累积阿片类药物消耗无显著差异(差值-4.630;98.3%CI,-9.530至0.272)。
  • 所有患者均实现完整切除,两组并发症率无显著差异(7.84% vs 8.00%,P=1.000)。
  • 术后6个月内无复发或死亡发生。

关键数值与推荐

  • 疼痛视觉模拟量表评分0-7天曲线下面积:剑突下组较侧肋间组低,差值-4.82(98.3%CI,-8.84至-0.80)。
  • 住院时间:两组差值0.318(98.3%CI,-0.190至0.825),无显著差异。
  • 术后累积阿片类药物消耗:两组差值-4.630(98.3%CI,-9.530至0.272),无显著差异。
  • 并发症率:剑突下组7.84% vs 侧肋间组8.00%(P=1.000),无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This trial was to evaluate the efficacy of subxiphoid approach thoracoscopic thymectomy for postoperative pain control and length of hospital stay compared with a lateral intercostal approach thoracoscopic thymectomy. METHODS: This multicenter, open-label, randomized clinical superiority trial enrolled 101 eligible participants clinically diagnosed with Masaoka-Koga I-II thymoma between August 15, 2021, and February 15, 2022. Each enrolled participant was randomized and underwent subxiphoid approach thoracoscopic thymectomy or lateral intercostal approach thoracoscopic thymectomy. A per-protocol analysis for each coprimary outcome was performed in addition to the main intention-to-treat analysis. RESULTS: In the analysis for the coprimary outcomes, the pain Visual Analog Scale score area under the curve at 0 to 7 days was lower in the subxiphoid approach thoracoscopic thymectomy group than in the lateral intercostal approach thoracoscopic thymectomy group (difference, -4.82; 98.3% CI, -8.84 to -0.80). However, there was no significant difference between the 2 groups in the length of hospital stay (difference, 0.318; 98.3% CI, -0.190 to 0.825) or cumulative opioid consumption after surgery (difference, -4.630; 98.3% CI, -9.530 to 0.272). All patients underwent complete resection, and there was no significant difference (7.84% vs 8.00%, P = 1.000) in the rate of complications between the 2 groups. No recurrence or death occurred in the postoperative 6 months. CONCLUSIONS: This study found improved pain and similar length of hospital stay associated with the subxiphoid approach compared with the lateral intercostal approach in patients with suspected Masaoka-Koga I-II thymoma.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang S, Yang X, Jiang J, et al. Subxiphoid versus lateral intercostal thoracoscopic thymectomy for suspected thymoma: Results of a randomized controlled trial. J Thorac Cardiovasc Surg. 2023. PMID: 37890660. doi:10.1016/j.jtcvs.2023.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。